• Please log in or register to access this feature.

Supplement

You have full text access to this OnlineOpen article

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy†

  1. Ludovic Ferrer MS1,2,‡,*,
  2. Françoise Kraeber-Bodéré MD, PhD2,3,4,
  3. Caroline Bodet-Milin MD2,4,
  4. Caroline Rousseau MD2,3,
  5. Stephen Le Gouill MD, PhD2,5,
  6. William A. Wegener MD, PhD6,
  7. David M. Goldenberg MD, PhD7,
  8. Manuel Bardiès PhD1,2,3,4

Article first published online: 2 FEB 2010

DOI: 10.1002/cncr.24797

Issue

Cancer

Cancer

Supplement: Cancer Therapy With Antibodies and Immunoconjugates, Supplement to Cancer

Volume 116, Issue Supplement 4, pages 1093–1100, 15 February 2010

Additional Information

How to Cite

Ferrer, L., Kraeber-Bodéré, F., Bodet-Milin, C., Rousseau, C., Gouill, S. L., Wegener, W. A., Goldenberg, D. M. and Bardiès, M. (2010), Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer, 116: 1093–1100. doi: 10.1002/cncr.24797

Author Information

  1. 1

    Medical Physics Department, CLCC Gauducheau, St Herblain, France

  2. 2

    INSERM UMR 892, Nantes, France

  3. 3

    Nuclear Medicine Department, CLCC Gauducheau, St Herblain, France

  4. 4

    Nuclear Medicine Department, University Hospital, Nantes, France

  5. 5

    Hematology Department, University Hospital, Nantes, France

  6. 6

    Immunomedics, Inc, Morris Plain, New Jersey

  7. 7

    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey

  1. ‡

    Fax: (011) 33 240 67 97 36

*Medical Physics Department, CLCC Gauducheau, St Herblain, France

  1. †

    The articles in this supplement were presented at the “12th Conference on Cancer Therapy with Antibodies and Immunoconjugates,” in Parsippany, New Jersey, October 16-18, 2008.

  2. ‡

    Fax: (011) 33 240 67 97 36

Publication History

  1. Issue published online: 2 FEB 2010
  2. Article first published online: 2 FEB 2010
  3. Manuscript Revised: 21 OCT 2009
  4. Manuscript Received: 30 JUN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (317K)

REFERENCES

  • 1
    Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006; 50: 248-264.
  • 2
    Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Cancer Biother Radiopharm. 2006; 21: 1-4.
  • 3
    Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991; 9: 548-564.
  • 4
    Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995; 55: 5899s-5907s.
  • 5
    Juweid M, Stadtmauer E, Sharkey RM, et al. Pharmacokinetics, dosimetry and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res. 1999; 5: 3292s-3303s.
  • 6
    Sharkey RM, Brenner A, Burton J, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti- CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003; 44: 2000-2018.
  • 7
    Linden O, Hindorf C, Cavalin-Stahl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005; 11: 5215-5222.
  • 8
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-epratuzumab: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003; 44: 77-84.
  • 9
    Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibodies Immunoconjugates Radioimmunopharm. 1990; 3: 213-233.
  • 10
    Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999; 40: 2102-2106.
  • 11
    Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993; 34: 689-694.
  • 12
    Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003; 44: 67-76.
  • 13
    Williams T, Kelley C. Available at: http://www.gnuplot. info. Accessed February 18, 2009.
  • 14
    Ferrer L, Carlier T, Lisbona A, Bardies M. An ImageJ plugin to create WB TAC using CT scanner. Eur. J Nucl Med. 2007; 34( suppl): S198.
  • 15
    Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH. Correction of photon attenuation and collimator response for a body-contouring spect/ct imaging system. J Nucl Med. 2005; 46: 868-877.
  • 16
    Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability. Neuroimage. 2006; 31: 1116-1128.
  • 17
    Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto SA. Practical method for position-dependent compton-scatter correction in single photon emission ct. IEEE Trans Med Imaging. 1991; 10: 408-412.
  • 18
    Thevenaz P, Ruttimann UE, Unser MA. Pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998; 7: 27-41.
  • 19
    Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum B. 1989; 16: 553-559.
  • 20
    Shen S, Meredith RF, Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting y-antibody therapy. J Nucl Med. 2002; 43: 1245-1253.
  • 21
    Feller PA, Sodd VJ, Kereiakes JG. Using the S tables of MIRD Pamphlet 11. J Nucl Med. 1977; 18: 747.
  • 22
    Juweid M, Sharkey RM, Siegel JA, Behr T, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res. 1995; 55: 5827s-5831s.
  • 23
    Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm. 2005; 20: 126-140.
  • 24
    Lim SM, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997; 38: 1374-1378.
  • 25
    DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997; 80: 2558s-2566s.
    Direct Link:
  • 26
    Meredith RF, Shen S, Forero A, LoBuglio AF. A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med. 2008; 49: 279-284.
  • 27
    Liu A, Williams LE, Raubitschek AA. A CT assisted method for absolute quantitation of internal radioactivity. Med Phys. 1996; 23: 1919-1928.
  • 28
    Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response–implications for radionuclide therapy. J Nucl Med. 2008; 49: 1884-1899.
View Full Article (HTML) Get PDF (317K)